{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:58:40Z","timestamp":1785308320574,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"DOI":"10.7759\/cureus.104921","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:08:36Z","timestamp":1773068916000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of In Vitro Effects of Fosfomycin in Combination With Amikacin and Ciprofloxacin Against Multidrug-Resistant Escherichia coli Isolates"],"prefix":"10.7759","author":[{"given":"Swadhin","family":"Choudhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumudini","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhra Snigdha","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Pattnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti Prakash","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310537","article-title":"Urinary tract infections caused by uropathogenic Escherichia coli: mechanisms of infection and treatment options","volume":"24","author":"Zhou Y","year":"2023","unstructured":"Zhou Y, Zhou Z, Zheng L, et al.. Urinary tract infections caused by uropathogenic Escherichia coli: mechanisms of infection and treatment options. Int J Mol Sci. 2023, 24:10537. 10.3390\/ijms241310537","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.12.009","article-title":"A nationwide population-based study of Escherichia coli bloodstream infections: incidence, antimicrobial resistance and mortality","volume":"28","author":"Feldman SF","year":"2022","unstructured":"Feldman SF, Temkin E, Wullfhart L, et al.. A nationwide population-based study of Escherichia coli bloodstream infections: incidence, antimicrobial resistance and mortality. Clin Microbiol Infect. 2022, 28:879-e1. 10.1016\/j.cmi.2021.12.009","journal-title":"Clin Microbiol Infect"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00031-8","article-title":"Emergence and dissemination of antimicrobial resistance in Escherichia coli causing bloodstream infections in Norway in 2002-17: a nationwide, longitudinal, microbial population genomic study","volume":"2","author":"Gladstone RA","year":"2021","unstructured":"Gladstone RA, McNally A, P\u00f6ntinen AK, et al.. Emergence and dissemination of antimicrobial resistance in Escherichia coli causing bloodstream infections in Norway in 2002-17: a nationwide, longitudinal, microbial population genomic study. Lancet Microbe. 2021, 2:e331-41. 10.1016\/S2666-5247(21)00031-8","journal-title":"Lancet Microbe"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13050411","article-title":"Multidrug-resistant bacteria in surgical intensive care units: antibiotic susceptibility and \u03b2-lactamase characterization","volume":"13","author":"Bandi\u0107 Pavlovi\u0107 D","year":"2024","unstructured":"Bandi\u0107 Pavlovi\u0107 D, Pospi\u0161il M, Na\u0111 M, et al.. Multidrug-resistant bacteria in surgical intensive care units: antibiotic susceptibility and \u03b2-lactamase characterization. Pathogens. 2024, 13:411. 10.3390\/pathogens13050411","journal-title":"Pathogens"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.001217","article-title":"The biogenesis of \u03b2-lactamase enzymes","volume":"168","author":"Kaderabkova N","year":"2022","unstructured":"Kaderabkova N, Bharathwaj M, Furniss RC, Gonzalez D, Palmer T, Mavridou DA. The biogenesis of \u03b2-lactamase enzymes. Microbiology (Reading). 2022, 168:001217. 10.1099\/mic.0.001217","journal-title":"Microbiology (Reading)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-12384-x","article-title":"Antibiotic resistance profiles and risk factors of multidrug-resistant Escherichia coli in a large tertiary care hospital in a low- and middle-income country","volume":"15","author":"Mousa N","year":"2025","unstructured":"Mousa N, Aiesh BM, Jomaa R, et al.. Antibiotic resistance profiles and risk factors of multidrug-resistant Escherichia coli in a large tertiary care hospital in a low- and middle-income country. Sci Rep. 2025, 15:26667. 10.1038\/s41598-025-12384-x","journal-title":"Sci Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11101333","article-title":"Prevalence of multidrug-resistant diarrheagenic Escherichia coli in Asia: a systematic review and meta-analysis","volume":"11","author":"Salleh MZ","year":"2022","unstructured":"Salleh MZ, Nik Zuraina NM, Hajissa K, Ilias MI, Deris ZZ. Prevalence of multidrug-resistant diarrheagenic Escherichia coli in Asia: a systematic review and meta-analysis. Antibiotics (Basel). 2022, 11:1333. 10.3390\/antibiotics11101333","journal-title":"Antibiotics (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07167-y","article-title":"A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011-2020","volume":"22","author":"Dunne MW","year":"2022","unstructured":"Dunne MW, Aronin SI, Yu KC, Watts JA, Gupta V. A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011-2020. BMC Infect Dis. 2022, 22:194. 10.1186\/s12879-022-07167-y","journal-title":"BMC Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab560","article-title":"Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management","volume":"73","author":"Kaye KS","year":"2021","unstructured":"Kaye KS, Gupta V, Mulgirigama A, et al.. Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management. Clin Infect Dis. 2021, 73:1992-9. 10.1093\/cid\/ciab560","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26189193","article-title":"Catheter-associated urinary tract infections: understanding the interplay between bacterial biofilm and antimicrobial resistance","volume":"26","author":"Tegegne DT","year":"2025","unstructured":"Tegegne DT, Abbott IJ, Po\u017aniak B. Catheter-associated urinary tract infections: understanding the interplay between bacterial biofilm and antimicrobial resistance. Int J Mol Sci. 2025, 26:9193. 10.3390\/ijms26189193","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/1040841X.2025.2548490","article-title":"Biofilm-associated Escherichia coli infections: pathogenesis, clinical implications, and treatment strategies","volume":"52","author":"Thakur D","year":"2026","unstructured":"Thakur D, Kumar L. Biofilm-associated Escherichia coli infections: pathogenesis, clinical implications, and treatment strategies. Crit Rev Microbiol. 2026, 52:198-242. 10.1080\/1040841X.2025.2548490","journal-title":"Crit Rev Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3934\/microbiol.2022019","article-title":"Biofilms: formation, drug resistance and alternatives to conventional approaches","volume":"8","author":"Mirghani R","year":"2022","unstructured":"Mirghani R, Saba T, Khaliq H, et al.. Biofilms: formation, drug resistance and alternatives to conventional approaches. AIMS Microbiol. 2022, 8:239-77. 10.3934\/microbiol.2022019","journal-title":"AIMS Microbiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-023-00164-w","article-title":"Biofilm formation: mechanistic insights and therapeutic targets","volume":"4","author":"Wang X","year":"2023","unstructured":"Wang X, Liu M, Yu C, Li J, Zhou X. Biofilm formation: mechanistic insights and therapeutic targets. Mol Biomed. 2023, 4:49. 10.1186\/s43556-023-00164-w","journal-title":"Mol Biomed"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12088-021-00988-6","article-title":"Potential inhibitors targeting Escherichia coli UDP-N-acetylglucosamine enolpyruvyl transferase (MurA): an overview","volume":"62","author":"Raina D","year":"2022","unstructured":"Raina D, Kumar C, Kumar V, Khan IA, Saran S. Potential inhibitors targeting Escherichia coli UDP-N-acetylglucosamine enolpyruvyl transferase (MurA): an overview. Indian J Microbiol. 2022, 62:11-22. 10.1007\/s12088-021-00988-6","journal-title":"Indian J Microbiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020153","article-title":"Assessment of in-vitro synergy of fosfomycin with meropenem, amikacin and tigecycline in whole genome sequenced extended and pan drug resistant Klebsiella pneumoniae: exploring a colistin sparing protocol","volume":"11","author":"Al-Quraini M","year":"2022","unstructured":"Al-Quraini M, Rizvi M, Al-Jabri Z, et al.. Assessment of in-vitro synergy of fosfomycin with meropenem, amikacin and tigecycline in whole genome sequenced extended and pan drug resistant Klebsiella pneumoniae: exploring a colistin sparing protocol. Antibiotics (Basel). 2022, 11:153. 10.3390\/antibiotics11020153","journal-title":"Antibiotics (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11274-022-03289-2","article-title":"Synergistic activity and molecular modelling of fosfomycin combinations with some antibiotics against multidrug resistant Helicobacter pylori","volume":"38","author":"Abouwarda AM","year":"2022","unstructured":"Abouwarda AM, Ismail TA, Abu El-Wafa WM, Faraag AH. Synergistic activity and molecular modelling of fosfomycin combinations with some antibiotics against multidrug resistant Helicobacter pylori. World J Microbiol Biotechnol. 2022, 38:102. 10.1007\/s11274-022-03289-2","journal-title":"World J Microbiol Biotechnol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/11.5.427","article-title":"The fractional inhibitory concentration (FIC) index as a measure of synergy","volume":"11","author":"Hall MJ","year":"1983","unstructured":"Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother. 1983, 11:427-33. 10.1093\/jac\/11.5.427","journal-title":"J Antimicrob Chemother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.8.1914","article-title":"Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test","volume":"40","author":"White RL","year":"1996","unstructured":"White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996, 40:1914-8. 10.1128\/AAC.40.8.1914","journal-title":"Antimicrob Agents Chemother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/0255-0857.19890","article-title":"Detection of biofilm formation among the clinical isolates of Staphylococci: an evaluation of three different screening methods","volume":"24","author":"Mathur T","year":"2006","unstructured":"Mathur T, Singhal S, Khan S, Upadhyay DJ, Fatma T, Rattan A. Detection of biofilm formation among the clinical isolates of Staphylococci: an evaluation of three different screening methods. Indian J Med Microbiol. 2006, 24:25-9. 10.4103\/0255-0857.19890","journal-title":"Indian J Med Microbiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-12366-z","article-title":"Isolation and identification of bacteriophage against Escherichia coli ATCC 25922 and their biofilm inhibition studies","volume":"15","author":"Sivakumar L","year":"2025","unstructured":"Sivakumar L, John Durai Kumar JV, Madhavan S, et al.. Isolation and identification of bacteriophage against Escherichia coli ATCC 25922 and their biofilm inhibition studies. Sci Rep. 2025, 15:26964. 10.1038\/s41598-025-12366-z","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed7090235","article-title":"Efficacy of fosfomycin against planktonic and biofilm-associated MDR uropathogenic Escherichia coli clinical isolates","volume":"7","author":"Dzib-Baak HE","year":"2022","unstructured":"Dzib-Baak HE, Uc-Cach\u00f3n AH, Dzul-Beh AJ, Rosado-Manzano RF, Gracida-Osorno C, Molina-Salinas GM. Efficacy of fosfomycin against planktonic and biofilm-associated MDR uropathogenic Escherichia coli clinical isolates. Trop Med Infect Dis. 2022, 7:235. 10.3390\/tropicalmed7090235","journal-title":"Trop Med Infect Dis"},{"key":"ref22","article-title":"M100: Performance Standards for Antimicrobial Susceptibility Testing, 34th\u00a0ed","author":"Clinical and Laboratory Standards Institute","year":"2023","unstructured":"Clinical and Laboratory Standards Institute. M100: Performance Standards for Antimicrobial Susceptibility Testing, 34th\u00a0ed. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania; 2023."},{"key":"ref23","unstructured":"R. A language and environment for statistical computing, Vienna, Austria. (2020). Accessed: February 11, 2026: https:\/\/www.r-project.org\/."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed7100281","article-title":"In vitro and in vivo effect of amikacin and imipenem combinations against multidrug-resistant E. coli","volume":"7","author":"Farhan SM","year":"2022","unstructured":"Farhan SM, El-Baky RM, Abdalla S, et al.. In vitro and in vivo effect of amikacin and imipenem combinations against multidrug-resistant E. coli. Trop Med Infect Dis. 2022, 7:281. 10.3390\/tropicalmed7100281","journal-title":"Trop Med Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/ani14131916","article-title":"In vitro antibacterial activities of fosfomycin against Escherichia coli isolates from canine urinary tract infection","volume":"14","author":"Jariyapamornkoon N","year":"2024","unstructured":"Jariyapamornkoon N, Nuanualsuwan S, Suanpairintr N. In vitro antibacterial activities of fosfomycin against Escherichia coli isolates from canine urinary tract infection. Animals (Basel). 2024, 14:1916. 10.3390\/ani14131916","journal-title":"Animals (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1387497","article-title":"A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli","volume":"14","author":"Nasrollahian S","year":"2024","unstructured":"Nasrollahian S, Graham JP, Halaji M. A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli. Front Cell Infect Microbiol. 2024, 14:1387497. 10.3389\/fcimb.2024.1387497","journal-title":"Front Cell Infect Microbiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.09.14","article-title":"Resistance mechanisms","volume":"4","author":"Cag Y","year":"2016","unstructured":"Cag Y, Caskurlu H, Fan Y, Cao B, Vahaboglu H. Resistance mechanisms. Ann Transl Med. 2016, 4:326. 10.21037\/atm.2016.09.14","journal-title":"Ann Transl Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos AS","year":"2011","unstructured":"Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011, 15:e732-9. 10.1016\/j.ijid.2011.07.007","journal-title":"Int J Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/472867-evaluation-of-in-vitro-effects-of-fosfomycin-in-combination-with-amikacin-and-ciprofloxacin-against-multidrug-resistant-escherichia-coli-isolates","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:08:38Z","timestamp":1773068918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/472867-evaluation-of-in-vitro-effects-of-fosfomycin-in-combination-with-amikacin-and-ciprofloxacin-against-multidrug-resistant-escherichia-coli-isolates"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.104921","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}